filmov
tv
Juno Therapeutics CEO Bishop on Immunotherapy

Показать описание
Jan.09 -- Juno Therapeutics CEO Hans Bishop discusses the company's immunotherapy for cancer. He speaks with Erik Schatzker on "Bloomberg Technology" from the JPMorgan Healthcare Conference.
Juno Therapeutics CEO Bishop on Immunotherapy
Juno Therapeutics CEO Bishop on Immunotherapy
Founder Stories: Hans Bishop, CEO of Juno Therapeutics and GRAIL
Juno Therapeutics' CEO and Work Experience - Q1 2019
Juno Manufacturing Plant
Juno Grand Opening [CC]
Juno co-founder and Fred Hatch colleagues launched an ambitious start-up to treat cancer
This can happen in Thailand
Juno Therapeutics
Juno Therapeutics | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks
Celgene to acquire Juno Therapeutics in $9B deal
Bayer HealthCare Specialty Medicine President Hans Bishop on Comparative Effectiveness
Natalie Portman having anxiety #natalieportman #shorts #shortsfeed #viral #subscribetomychannel
Uniquely HR Testimonial by Robin at Juno Therapeutics
Working at Juno Therapeutics - May 2018
Panel: Next Generation CARs and Other Cell-based Immunotherapies
Lecture: Juno´s Cell Handling Platform, Dr. Germeroth
Digging into Deals: Why Celgene Joined Up With Juno Therapeutics In 2015
Dorothy Freedom use case #1: Kite Pharmaceuticals vs. Juno Therapeutics.
This Is Not Normal Behavior
Crazy tick removal? Or fake?
[amanda bynes] before vs after drugs 😰 | #shorts #shortsfeed #fyp #amandabynes
Bristol Myers Squibb exec on the company’s growth in Seattle and beating cancer with immune cells
Celgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations || CAR-T ||Juno Therapeutics, Inc.
Комментарии